Alerts
Myeloma Gets an Accelerated Approval. The Endpoint Is the Politics.
FDA has granted accelerated approval to iberdomide with daratumumab and dexamethasone for relapsed or refractory multiple myeloma after at least one prior line of therapy. The approval moves a CELMoD earlier into the myeloma pathway, but it also puts MRD and confirmatory evidence back under the spotlight.
Europe’s Safe Hearts Plan Makes Prevention a Political Test
England’s Tirzepatide Rollout Shows Approval Is Not Access
Medicare’s GLP-1 Bridge Turns Obesity Coverage Into a Public-Payer Experiment
WHO Makes Obesity Treatment a Global Access Test
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Huntington Gene Therapy Hits the Evidence Wall
Rare Disease Policy Moves Into the Individualised Therapy Era
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
AI Mental Health Support Becomes a Governance Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.